The Medtronic Newsroom is designed to assist media in finding news and information about our company.
Medtronic, founded in a Minneapolis garage in 1949 by Earl Bakken and his brother-in-law, Palmer Hermundslie, is the world’s leading maker of medical devices.
Our Mission has not changed since Earl Bakken wrote it in 1960: To contribute to human welfare by application of biomedical engineering in the research, design, manufacture, and sale of instruments or appliances that alleviate pain, restore health and extend life.
More than 9 million lives are enhanced every year by a Medtronic product or therapy; that’s one every three seconds.
Medtronic is headquartered in Minneapolis, MN and operates in more than 140 countries. The company employs 49,000 people, including 5,800 scientists and engineers, pursuing research and innovation that has led to more than 28,000 patents.
|11/28/14||European Commission Clears Medtronic Acquisition of Covidien|
MINNEAPOLIS AND DUBLIN, Ireland - Nov. 28, 2014 - Medtronic, Inc. (NYSE: MDT) and Covidien plc (NYSE: COV) today announced that the European Commission has conditionally cleared Medtronic's proposed acquisition of Covidien. The clearance decision is conditional on Medtronic's commitment to divest Covidien's drug coated balloon business. As previously announced, a subsidiary of Covidien entered into an agreement to divest Covidien's drug coated balloon busin... |
|11/26/14||Medtronic Acquisition of Covidien Receives U.S. FTC Clearance|
|MINNEAPOLIS AND DUBLIN, Ireland - Nov. 26, 2014 - Medtronic, Inc. (NYSE: MDT) and Covidien plc (NYSE: COV) today announced the receipt of U.S. Federal Trade Commission (FTC) clearance of Medtronic's proposed acquisition of Covidien. "This regulatory clearance represents an important milestone in bringing our companies together," said Omar Ishrak, Chairman and CEO of Medtronic. "We continue to make good progress in planning for the integration of these two companies which will u... |
|11/18/14||Medtronic Reports Second Quarter Earnings|
|Revenue of $4.4 Billion Grew 5% on Constant Currency Basis; 4% as Reported
Non-GAAP Diluted EPS of $0.96, Growth of 5%; GAAP Diluted EPS of $0.83, Decline of 7%
Company Updates FY15 Revenue Growth Outlook; Reiterates FY15 EPS Guidance
Company Reaffirms Commitment to Covidien Transaction
MINNEAPOLIS - Nov. 18, 2014 - Medtronic, Inc. (NYSE: MDT) today announced financial results for its second quarter of fiscal year 2015, which ended October 24, 2014.
The company reported worldwide seco... |
|Receive E-mail Alerts |
|Sign up to receive e-mail alerts whenever Medtronic posts new information to the site. Just enter your e-mail address and click Submit.|